Company intelligence / Profile preview

Loema

Loos, Hauts-de-France, France

Ownership: Private
Development stage: Other

Overview

Loema is a French biotechnology company focused on developing first-in-class therapies for rare diseases, specifically Loeys-Dietz Syndrome (LDS). Founded in 2022 by former Genfit executives, the company is headquartered in Lille and targets the TGF-beta signaling pathway to treat connective tissue disorders. Its lead program, LOE-001, is an oral small molecule therapeutic aimed at preventing aortic aneurysms and other vascular complications in LDS patients. Loema's approach combines deep biological insights with a focused development strategy to address high unmet medical needs in the rare disease space.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Loema.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Loema.

Explore the full profile